Cell Signaling Technology

Phospho-4E-BP1 (Thr70) Antibody

#9455 · $362,852

63
Evidence Score · Well-Established
Used by 144 independent labs across 162 papers. How we score this →
100
Citing papers
9.1k
Combined citations
Supplier page Find this product

Research areas

Lung Cancer Treatments and Mutations19PI3K/AKT/mTOR signaling in cancer17Cancer Cells and Metastasis15MicroRNA in disease regulation10Cancer-related molecular mechanisms research8Cancer, Hypoxia, and Metabolism6RNA modifications and cancer6Cytokine Signaling Pathways and Interactions5

Papers citing this product

1
An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)
Cell Death and Disease·2013·467 cit.·DOI
2
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
Proceedings of the National Academy of Sciences·2010·385 cit.·DOI
3
Screen for Chemical Modulators of Autophagy Reveals Novel Therapeutic Inhibitors of mTORC1 Signaling
PLoS ONE·2009·345 cit.·DOI
4
IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling
Journal of Thoracic Oncology·2016·301 cit.·DOI
5
Estrogen Stimulates Postsynaptic Density-95 Rapid Protein Synthesis via the Akt/Protein Kinase B Pathway
Journal of Neuroscience·2003·196 cit.·DOI
6
P2Y2 and Gq/G11 control blood pressure by mediating endothelial mechanotransduction
Journal of Clinical Investigation·2015·195 cit.·DOI
7
Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosis
Nature Communications·2018·192 cit.·DOI
8
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
Clinical & Experimental Metastasis·2008·192 cit.·DOI
9
MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting <i>MAGI2</i> in Lung Adenocarcinoma Cells
Molecular Cancer Therapeutics·2013·186 cit.·DOI
10
JAK1 Activates STAT3 Activity in Non-Small–Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling
Molecular Cancer Therapeutics·2011·180 cit.·DOI

Similar products

ProductVendorEvidencePricePapers
Phospho-4E-BP1 (Thr70) (D7F6I) Rabbit Monoclonal AntibodyRabbitCell Signaling Technology63$176,41561

Rate this reagent

Used this in your lab? Leave a quick rating. Reviews are anonymous and verified by academic email before they appear.

Your email is never shown publicly.